Cixutumumab IMC-A12; NSC742460|cas:947687-12-9|西域试剂

Cixutumumab IMC-A12; NSC742460,97.57%

产品编号：Bellancom-P99189| CAS NO：947687-12-9

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99189	￥2900.00	杭州北京（现货）
Bellancom-P99189	￥7200.00	杭州北京（现货）
Bellancom-P99189	￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cixutumumab IMC-A12; NSC742460

产品介绍

Cixutumumab (IMC-A12) 是一种具有高亲和力的人源化抗 IGF-1R 单克隆抗体，抑制配体依赖的受体激活和下游信号传导。Cixutumumab 还介导 IGF-IR 的内化和降解。Cixutumumab 具有广谱抗肿瘤活性，可用于肺癌、恶性肿瘤、白血病、非小细胞肺癌和前列腺癌等癌症的研究。

生物活性

Cixutumumab (IMC-A12) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.

体外研究

Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	CHLA-9, TC-71, Rh41 cells
Concentration:	0.01-100 nM
Incubation Time:	96 h
Result:	Inhibited CHLA-9, TC-71and Rh41 cells growth with IC₅₀ values of 49.31, 0.66 and 0.04 nM, respectively.

体内研究
(In Vivo)

Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CB17SC-M scid^-/- female mice (solid tumor xenografts model).
Dosage:	1 mg/rat
Administration:	Intraperitoneal injection; twice weekly for 6 weeks.
Result:	Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.

体内研究

Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CB17SC-M scid^-/- female mice (solid tumor xenografts model).
Dosage:	1 mg/rat
Administration:	Intraperitoneal injection; twice weekly for 6 weeks.
Result:	Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.

体内研究

Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CB17SC-M scid^-/- female mice (solid tumor xenografts model).
Dosage:	1 mg/rat
Administration:	Intraperitoneal injection; twice weekly for 6 weeks.
Result:	Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression.